Incident genital HPV infections and potential impact of HPV vaccines in adult women living with HIV/AIDS

Figures & data

Table 1. Social, epidemiological and clinical characteristics of women at baseline evaluation.

Characteristics of women enrolled		N (%)
Country or continent of origin	Italy	464 (82.1)
	Africa	61 (10.8)
	Asia	6 (1.1)
	Central/South America	17 (3.0)
	Europe	17 (3.0)
Education	Primary school	272 (48.1)
	Secondary school	244 (43.2)
	Degree	48 (8.5)
	Unknown	1 (0.2)
Smoking habits	Smoker	256 (45.3)
	Non smoker	197 (34.9)
	Previous smoker	112 (19.8)
N of lifetime sexual partners	1	46 (8.1)
	2–5	285 (50.4)
	>5	231 (40.9)
	Not known	3 (0.5)
N of sexual partners in the last 6 months	0	152 (26.9)
	1	401 (71.0)
	2–3	8 (1.4)
	>3	1 (0.2)
	Not known	3 (0.5)
History of Sexually Transmitted Infections (STIs)	≥ 1 STI	300 (53.1)
	No STI	260 (46.0)
	Not known	5 (0.9)
Mode of HIV infection	Sexual	436 (77.2)
	Parenteral	124 (21.9)
	Mother-to-child	5 (0.9)
CDC stage of HIV	A	254 (45.0)
	B	119 (21.0)
	C	121 (21.4)
	Not known	71 (12.6)
HIV viral load	Undetectable	437 (77.3)
	(< 37 copies/mL)	126 (22.3)
	Detectable	2 (0.3)
	(>37 copies/mL)
	Not known
Currently taking Antiretroviral treatment	Yes	525 (92.9)
	No^a	40 (7.1)
Antiretroviral treatment line	1st	111 (19.6)
	2nd	94 (16.6)
	3rd	62 (11.0)
	>3rd	251 (44.4)
	Not known	47 (8.3)
Age (years): median (IQR)		43 (37–47)
Baseline CD4+: median cells/µL (IQR)		569.5 (409–770.8)
Nadir CD4+: median cells/µL (IQR)		200 (100–300)
HIV viral load: mean log copies/mL (SD)		1.85 (0.83)

^a38 patients (6.7%) were not on antiretroviral treatment according to the Italian guidelines for antiretroviral treatment

Table 2. Cervical abnormalities at baseline evaluation and prevalence rate of HPV infections among HIV-infected women.

	Result	N	% (95%CI)
Cytology (N = 565)	NILM	485	85.8 (82.6–88.6)
	ASC-US	28	5.0 (3.4–7.2)
	LSIL	43	7.6 (5.6–10.2)
	AGC	3	0.5 (0.1–1.7)
	ASC-H	2	0.3 (0.1–1.4)
	HSIL	4	0.7 (0.2–1.9)
Histology (N = 44)	Neg	21	47.7 (32.7–63.1)
	CIN1	12	27.3 (15.5–43.0)
	VAIN1	1	2.3 (0.1–13.5)
	CIN2	3	6.8 (1.8–19.7)
	CIN3	2	4.5 (0.8–16.7)
	Inadequate	5	11.4 (4.3–25.4)
HPV (any type) (N = 565)	Pos	153	27.1 (23.5–31.0)
HR-HPV (N = 565)	Pos	127	22.5 (19.1–26.2)

Figure 1. HPV types detected at baseline (a), during follow-up (b) and in incident infections (c) grouped according to the IARC classification. The genotypes included in 2v-, 4v-, or 9-v-HPV vaccines are coloured blue and green.

Figure 2. Percentage of HPV types detected in 28 incident SILs (blue bars) and in 4 HSILs (red bars).